Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis

Gossage, DL; Cieslarova, B; Ap, S; Zheng, H; Xin, Y; Lal, P; Chen, G; Smith, V; Sundy, JS

Gossage, DL (reprint author), Gilead Sci Inc, 199 E Blaine St, Seattle, WA 98102 USA.

CLINICAL THERAPEUTICS, 2018; 40 (1): 156

Abstract

Purpose: Andecaliximab (GS-5745) is a highly selective monoclonal antibody against matrix metalloproteinase-9 (MMP9), a proteolytic enzyme implicated ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索